Segment Information

9 Months Ended

Mar. 31, 2020

Note 13. Segment Information

The Company has one operating and reporting segment (oncology systems group), which develops, manufactures and markets proprietary medical devices used in radiation therapy for the treatment of cancer patients. The Company’s Chief Executive Officer, its Chief Operating Decision Maker, reviews financial information presented on a consolidated basis for purposes of making operating decisions and assessing financial performance. The Company does not assess the performance of its individual product lines on measures of profit or loss, or asset-based metrics. Therefore, the information below is presented only for revenues and long-lived tangible assets by geographic area.

Disaggregation of Revenues

The Company disaggregates its revenues from contracts by geographic region, as the Company believes this best depicts how the nature, amount, timing and uncertainty of revenues and cash flows are affected by economic factors. Additionally, the Company typically recognizes revenue at a point in time for product revenue and recognizes revenue over time for service revenue.

Revenues attributed to a country or region is based on the shipping addresses of the Company’s customers. The following summarizes revenue by geographic region (in thousands):

	Three Months Ended March 31,				Nine Months Ended March 31,
	2020		2019		2020		2019
Americas	$	34,738	$	31,616	$	96,560	$	92,559
Europe, Middle East, India and Africa		23,027		32,943		88,626		110,919
Asia Pacific		20,384		17,070		49,266		47,922
Japan		21,399		21,592		53,499		49,968
Total	$	99,548	$	103,221	$	287,951	$	301,368

Information regarding geographic areas in which the Company has long-lived tangible assets is as follows (in thousands):

	March 31,		June 30,
	2020		2019
Americas	$	13,560	$	13,853
Europe, Middle East, India and Africa		372		575
Asia Pacific		1,098		1,419
Japan		1,272		1,275
Total	$	16,302	$	17,122